Avalon GloboCare Corp. (AVCO): Price and Financial Metrics
GET POWR RATINGS... FREE!
AVCO POWR Grades
- Momentum is the dimension where AVCO ranks best; there it ranks ahead of 66.24% of US stocks.
- AVCO's strongest trending metric is Sentiment; it's been moving up over the last 31 weeks.
- AVCO's current lowest rank is in the Value metric (where it is better than 3.05% of US stocks).
AVCO Stock Summary
- AVCO has a market capitalization of $81,989,682 -- more than approximately merely 11.29% of US stocks.
- Avalon GloboCare Corp's stock had its IPO on November 6, 2018, making it an older stock than merely 7.21% of US equities in our set.
- AVCO's price/sales ratio is 60.75; that's higher than the P/S ratio of 95.66% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Avalon GloboCare Corp are EMX, ASM, TDOC, FTFT, and VCTR.
- Visit AVCO's SEC page to see the company's official filings. To visit the company's web site, go to www.avalon-globocare.com.
AVCO Valuation Summary
- In comparison to the median Healthcare stock, AVCO's price/sales ratio is 1647.37% higher, now standing at 66.4.
- Over the past 34 months, AVCO's price/earnings ratio has gone up 30.4.
- AVCO's EV/EBIT ratio has moved up 32.2 over the prior 34 months.
Below are key valuation metrics over time for AVCO.
AVCO Stock Price Chart Interactive Chart >
AVCO Price/Volume Stats
|Current price||$0.96||52-week high||$1.65|
|Prev. close||$0.96||52-week low||$0.80|
|Day high||$0.97||Avg. volume||356,353|
|50-day MA||$0.97||Dividend yield||N/A|
|200-day MA||$1.10||Market Cap||82.07M|
Avalon GloboCare Corp. (AVCO) Company Bio
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. In addition, the company develops proprietary diagnostic and therapeutic products leveraging exosome technology; and provides development services for hospitals. The company has a strategic partnership with Weill Cornell Medical College to co-develop bio-production and standardization procedures for chimeric antigen receptor (CAR)-T Therapy; GensKey Medical Technology Co. Ltd. to co-develop and commercialize point-of-care, rapid detection antibody tests to identify whether a patient has been exposed to and has developed antibodies against SARS-CoV-2; GE Healthcare to enhance standardized automation and bio-production for cellular medicines; and HydroPeptide, LLC to co-develop and commercialize various clinical-grade, exosome-based cosmeceutical and orthopedic products, as well as research agreement with Massachusetts Institute of Technology to develop CAR technology. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.
Most Popular Stories View All
AVCO Latest News Stream
|Loading, please wait...|
AVCO Latest Social Stream
View Full AVCO Social Stream
Latest AVCO News From Around the Web
Below are the latest news stories about Avalon GloboCare Corp that investors may wish to consider to help them evaluate AVCO as an investment opportunity.
FREEHOLD, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that it will be presenting at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 – 30, 2021. David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer of Avalon GloboCare will present on Thursday,
HERNDON, Va., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sysorex (OTCQB: SYSX) (“Sysorex” or the “Company”), the preeminent, U.S.-based, publicly traded Ethereum mining and technologies company, today announced that it has elected William B. Stilley, III to the Company’s Board of Directors and as Chair of the Board’s Audit Committee. The Company also expanded the size of its Board to five directors and established its Audit Committee. Mr. Stilley is the Chief Executive Officer of Adial Pharmaceuticals,
INVESTIGATION: Halper Sadeh LLP Investigates INOV, SAFM, LMRK, AVCO, TRIL, XENT; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
AVALON GLOBOCARE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Avalon GloboCare Corp. - AVCO
NEW ORLEANS, September 08, 2021--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Hebei Senlang Biotechnology Co. Ltd. to Avalon GloboCare Corp. ("the Company") (NasdaqCM: AVCO). Under the terms of the proposed transaction, Avalon will reportedly issue 81 million shares of its common stock to acquire SenlangBio. KSF is seeking to determine whether the merger and the process that led to it are
PITTSBURGH, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and New Jersey-based biotechnology company Avalon GloboCare Corp. (NASDAQ: AVCO) aims to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring these powerful treatments to cancer patients within days instead of weeks. Cancer immunotherapy, which stimulates and trains a patient’s own immune system to target and kill tumors while lea
AVCO Price Returns